Pacira BioSciences Defends 5x30 Strategy Amid Proxy Fight with DOMA

Event summary

  • Pacira BioSciences mailed a letter to stockholders on May 5, 2026, urging votes for its nominees ahead of the June 9, 2026, annual meeting.
  • The company reported a 30% stock increase since launching its 5x30 strategy in January 2025, with Q1 2026 revenue up 5% year-over-year to $177 million.
  • Pacira highlighted progress in its 5x30 strategy, including treating 2.5 million patients in 2025 and securing reimbursement for 110 million lives under the NOPAIN Act.
  • DOMA Perpetual Capital Management proposed three unqualified director candidates and advocated for cost cuts, pipeline discontinuation, and a potential sale of the company.

The big picture

Pacira BioSciences is defending its 5x30 growth strategy against DOMA Perpetual Capital Management's proxy challenge, highlighting strong Q1 2026 results and progress in patient volume and product revenue. The company's focus on non-opioid pain therapies aligns with broader industry trends toward opioid-sparing treatments, but the governance battle could disrupt its long-term strategic execution. The outcome of the June 9, 2026, annual meeting will be critical in determining the company's future direction.

What we're watching

Governance Dynamics
Whether Pacira can maintain board independence and strategic direction amid DOMA's proxy challenge.
Execution Risk
The pace at which Pacira advances its 5x30 strategy, particularly in pipeline development and partnerships.
Market Response
How investors react to Pacira's defense of its strategy versus DOMA's proposed changes.